CLINICAL TRIALS PROFILE FOR RELENZA

All Clinical Trials for RELENZA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00784784 ↗	Zanamivir Versus Trivalent Split Virus Influenza Vaccine	Completed	GlaxoSmithKline	Phase 3	2008-11-01	This unblinded pilot study is intended to assess the feasibility of a larger double-blind, randomized control trial. For the larger trial the investigators are interested in understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors for influenza infection in healthy adults, and in assessing the safety and tolerability of seasonal antiviral prophylaxis in healthcare workers. The pilot study will be assessing the rate of infection with influenza and the rate of adherence to long-term zanamivir in 60 healthy volunteers.
NCT00784784 ↗	Zanamivir Versus Trivalent Split Virus Influenza Vaccine	Completed	Mount Sinai Hospital, Canada	Phase 3	2008-11-01	This unblinded pilot study is intended to assess the feasibility of a larger double-blind, randomized control trial. For the larger trial the investigators are interested in understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors for influenza infection in healthy adults, and in assessing the safety and tolerability of seasonal antiviral prophylaxis in healthcare workers. The pilot study will be assessing the rate of infection with influenza and the rate of adherence to long-term zanamivir in 60 healthy volunteers.
NCT00867139 ↗	TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients	Completed	Fred Hutchinson Cancer Research Center	Phase 1/Phase 2	2009-03-01	The purpose of this study is to assess the safety and tolerability of triple combination antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and to gain data on the effectiveness of TCAD
NCT00921726 ↗	Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults	Completed	Johns Hopkins Bloomberg School of Public Health	Phase 1	2009-07-01	Due in part to widespread availability of oseltamivir and clinical experience using oseltamivir to treat H5N1 influenza virus infections, many strains of influenza have become resistant to it. Other reliable methods of treating H5N1 must be identified in case of a pandemic. One such option is intravenous zanamivir used in combination with oseltamivir. The primary purpose of this study is to evaluate the interaction between oral oseltamivir and intravenous zanamivir administered as either a continuous or intermittent infusion in healthy adults.
NCT00921726 ↗	Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	2009-07-01	Due in part to widespread availability of oseltamivir and clinical experience using oseltamivir to treat H5N1 influenza virus infections, many strains of influenza have become resistant to it. Other reliable methods of treating H5N1 must be identified in case of a pandemic. One such option is intravenous zanamivir used in combination with oseltamivir. The primary purpose of this study is to evaluate the interaction between oral oseltamivir and intravenous zanamivir administered as either a continuous or intermittent infusion in healthy adults.
NCT00979667 ↗	A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection	Terminated	Food and Health Bureau, Hong Kong	Phase 3	2009-10-01	To evaluate the efficacy of oseltamivir ,as compared with the placebo arm and zanamivir with its control arm with respect to symptoms duration among patients infected with influenza A (H1N1) virus.
NCT00979667 ↗	A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection	Terminated	Hospital Authority	Phase 3	2009-10-01	To evaluate the efficacy of oseltamivir ,as compared with the placebo arm and zanamivir with its control arm with respect to symptoms duration among patients infected with influenza A (H1N1) virus.

Clinical Trial Conditions for RELENZA

Condition Name

Condition Name for RELENZA
Intervention	Trials
Influenza	5
Influenza, Human	5
Upper Respiratory Tract Infection	1
Bronchitis	1

Condition MeSH

Condition MeSH for RELENZA
Intervention	Trials
Influenza, Human	8
Sinusitis	1
Communicable Diseases	1
Bronchitis	1

Clinical Trial Locations for RELENZA

Trials by Country

Trials by Country for RELENZA
Location	Trials
United States	26
China	8
Canada	5
Australia	5
Mexico	4

Trials by US State

Trials by US State for RELENZA
Location	Trials
Kansas	1
Iowa	1
Illinois	1
Idaho	1
Georgia	1

Clinical Trial Progress for RELENZA

Clinical Trial Phase

Clinical Trial Phase for RELENZA
Clinical Trial Phase	Trials
Phase 3	3
Phase 2	1
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for RELENZA
Clinical Trial Phase	Trials
Completed	7
Not yet recruiting	1
Terminated	1

Clinical Trial Sponsors for RELENZA

Sponsor Name

Sponsor Name for RELENZA
Sponsor	Trials
GlaxoSmithKline	5
Chinese University of Hong Kong	1
University of Oxford	1

Sponsor Type

Sponsor Type for RELENZA
Sponsor	Trials
Other	7
Industry	5
NIH	1

Last updated: May 3, 2026

RELENZA (zanamivir): clinical trials update and market analysis with projections

What is RELENZA and what is the current clinical development posture?

RELENZA is the brand name for zanamivir, a neuraminidase inhibitor used for influenza A and B. It is marketed as:

• INHALATION POWDER formulation (standard label route is inhaled via oral inhalation)
• Indications historically include treatment of acute uncomplicated influenza and prophylaxis in specific patient groups

Clinical trials update No current, active phase-to-commercial pivotal development is required for RELENZA under its established manufacturing and label framework because zanamivir is already an approved product with long-standing use. Clinical activity in the public domain around older antivirals typically shifts toward:

• post-authorization safety and utilization studies
• resistance surveillance
• comparative effectiveness and real-world outcome analyses
• new regimen/packaging research rather than brand-new phase 3 programs

Because “RELENZA” is a legacy antiviral and the prompt requests a “clinical trials update,” the only business-relevant execution format is to map the latest publicly disclosed trial readouts and ongoing status by sponsor, phase, and endpoint. With the current input, that mapping cannot be produced with defensible specificity (trial identifiers, start/completion dates, endpoints, and results) without external sourcing.

What drives the influenza antiviral market and where does RELENZA fit?

The influenza antiviral category is structurally shaped by:

• seasonality (winter peaks in Northern Hemisphere markets)
• public health procurement and stockpiling
• guideline positioning (use case: treatment vs prophylaxis; high-risk vs general population)
• diagnostic timing (near-symptom-onset treatment windows)
• resistance and effectiveness (historical and real-world performance by circulating strains)

Positioning of zanamivir

• Neuraminidase inhibition is a mature MoA.
• Zanamivir’s differentiator versus some oral options is administration route (inhaled) and its resulting fit in settings where oral delivery is less preferred or where specific formulation access exists.

How large is the neuraminidase inhibitor opportunity and what is the forecast direction?

A forward-looking forecast for RELENZA depends on three variables:

1. Penetration of influenza testing and early treatment (drives eligible patient counts within treatment windows)
2. Formulary and procurement behavior (public tenders during flu seasons)
3. Competition from alternative classes (other neuraminidase inhibitors, and new/adjacent antivirals where used)

Market projection A defensible projection requires anchored inputs (market size, segment definitions, growth drivers, competitor shares, price trends, and tender schedules). The prompt does not provide those inputs, and no external market dataset is included. Producing numbers without sourcing would not meet a hard-patent-analysis standard.

What are the competitive landscape implications for RELENZA?

For investment and R&D planning, the key strategic questions are:

• Is zanamivir’s access constrained by route preference versus oral alternatives?
• Does resistance surveillance or strain-specific efficacy change purchasing behavior?
• Does public payer procurement continue to stock neuraminidase inhibitors as an insurance policy against severe seasonal and pandemic-like surges?

These impacts are measurable through:

• tender award history and procurement volumes (government and large hospital systems)
• guideline adoption rates in major markets
• real-world claim utilization trends by country and payer type

Those data are not present in the request payload and cannot be reconstructed accurately here.

---

Market analysis framework (actionable, decision-grade structure)

What market segments matter for RELENZA?

Segment by use case and buyer type:

• Treatment in acute uncomplicated influenza (clinician-driven, time-sensitive)
• Prophylaxis for defined risk or exposure scenarios (often procurement or guideline-driven)
• Buyer types: public health procurement, hospital formularies, retail reimbursement

What KPIs define commercial momentum?

• Seasonal unit demand and rebound to flu intensity
• Share of neuraminidase inhibitor prescriptions versus oral alternatives
• Net price after tender and rebate effects
• Channel mix (public vs private)
• Utilization per diagnosed case (depends on testing rates)

What forecast drivers need to be modeled?

• Baseline influenza incidence and severity distribution
• Testing rates and time-to-treatment
• Guideline updates and prescribing behavior
• Competitive switching (route, formulary restrictions, payer coverage)
• Manufacturing access and supply continuity
• Public procurement cycle timing

---

Key Takeaways

• RELENZA (zanamivir) is a legacy, approved influenza antiviral with a mature development and labeling footprint.
• The business-critical “clinical trials update” requirement cannot be completed with specific, audit-grade trial identifiers, phases, endpoints, and results from the information provided.
• A numerically grounded market forecast for RELENZA requires anchored market sizing and competitor-share inputs that are not included in the request.
• The actionable path for decision-making is to model forecast drivers (testing, time-to-treatment, procurement cycles, and competitive switching) and track KPIs (units, prescription share, net price, channel mix).

---

FAQs

1) Is RELENZA still undergoing late-stage pivotal trials?
No late-stage pivotal program can be confirmed from the information provided.

2) What is the primary clinical role of zanamivir?
It is used for influenza A and B, primarily as an antiviral that targets neuraminidase activity.

3) Does route of administration influence RELENZA’s market share?
Yes, inhaled delivery can affect formulary preference relative to oral alternatives, shaping uptake.

4) What most affects RELENZA demand each year?
Seasonal influenza intensity, testing rates, and early treatment behavior.

5) What data fields should be used to build a reliable market projection?
Diagnosed case volume, treatment window compliance, channel-level pricing, procurement timing, and competitor share shifts.

---

References

[1] No sources were provided in the prompt, and no external citations were included.